Anavex Life Sciences Corp (AVXL)

[bas2020]

You can't treat the 15% miss as purely by chance (i.e. coin flip). You must take qualitative factors into consideration.

My point is that based ONLY on the 85% success rate that doesn't tell you which of the applications will be in the 85% or the 15%.

For one, what were the AEs for the 15% that didn't get accepted?

Qualitatively, blarcamesine is looking rather good with both efficacy and safety profiles.
No worries here about approval this year.